No Data
No Data
Cathay Biotech: third quarter report 2024
Third Quarter Report 2024
Cathay biotech inc. (688065.SH) announced its performance for the first three quarters, with a net income of 0.345 billion yuan, a year-on-year increase of 9.97%.
Cathay Biotech Inc. (688065.SH) disclosed its third quarter report for 2024, achieving operating income for the first three quarters...
Is Cathay Biotech (SHSE:688065) Using Too Much Debt?
Cathay Biotech Inc. (688065.SH): The controlling shareholder proposed the company to repurchase shares.
On October 16, Cathay Biotech Inc. (688065.SH) announced that the company's controlling shareholder, Cathay Industrial Biotech Ltd. (referred to as the 'controlling shareholder' or 'CIB'), issued a 'Letter on the Proposal for Cathay Biotech Inc. Shanghai to Repurchase Company Shares.' The controlling shareholder proposed that the company use its own funds to repurchase some of the RMB common shares (A shares) issued by Cathay Biotech Inc. Shanghai through the Shanghai Stock Exchange's trading system using centralized competitive bidding trading. The total amount of the repurchase funds shall not be less than RMB 10 million and not exceed RMB 20 million.
Cathay Biotech Inc. (688065.SH): The company develops bio-based polyamide composite materials, bio-based long-chain polyamide, and other products that can be applied to power batteries, energy storage, automobile thermal management components, etc.
Geelonghui September 18th | Cathay Biotech Inc. (688065.SH) stated on the investor interaction platform that new energy is one of the important application areas of the company's bio-based new materials. The company's developed bio-based polyamide composite materials, bio-based long-chain polyamide, and other products can be applied to power batteries, energy storage, autos' thermal management components, etc. At present, the company and its partners are jointly conducting product trial production and verification.
No Data
No Data